Low dosis of alteplase, for ischemic stroke after Enchanted and its determinants, a single center experience
Arq. neuropsiquiatr; 78 (11), 2020
Abstract Background: Low-dose alteplase (LrtPA) has been shown not to be inferior to the standard-dose (SrtPA) with respect to death/disability. Objective: We aim to evaluate the percentage of patients treated with LrtPA at our center after the ENCHANTED trial and the factors associated with the use of...